Catalyst Pharmaceutical Partners Reaches New 12-Month High at $2.61 (CPRX)
Catalyst Pharmaceutical Partners (NASDAQ:CPRX)’s share price reached a new 52-week high during trading hours on Wednesday, Stock Ratings Network.com reports. The company traded as high as $2.61 and last traded at $2.58, with a volume of 4,110,718 shares traded. The stock had previously closed at $2.36.
Several analysts have recently commented on the stock. Analysts at Aegis raised their price target on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) from $3.50 to $4.00 in a research note to investors on Friday, September 6th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “hold” rating on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) in a research note to investors on Tuesday, August 27th. They now have a $1.00 price target on the stock.
Catalyst Pharmaceutical Partners has a one year low of $0.37 and a one year high of $2.50. The stock has a 50-day moving average of $1.53 and a 200-day moving average of $0.9. The company’s market cap is $106.6 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.07) by $0.01. On average, analysts predict that Catalyst Pharmaceutical Partners will post $-0.25 earnings per share for the current fiscal year.
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.